MedTrace Logo

Blood Biomarkers for Screening of Alzheimer's Disease

NCT06477484 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 180

Last updated 2024-06-27

No results posted yet for this study

Summary

The goal of this observational study is to estimate the screen performance of blood biomarkers of interest (Aβ40 and Aβ42, P-Tau181, P-Tau217, GFAP and NfL) in patients with Alzheimer's disease (AD), mild cognitive impairment due to AD, and cognitively normal individuals. The main questions it aims to answer are:

* to identify core blood biomarker suitable for early screening of AD.
* to establish a comprehensive model for the early identification of AD.

Conditions

Interventions

DIAGNOSTIC_TEST

Blood biomarker

Blood biomarker

Sponsors & Collaborators

  • Peking University First Hospital

    lead OTHER

Eligibility

Min Age
50 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-06-18
Primary Completion
2026-03-26
Completion
2026-03-26

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06477484 on ClinicalTrials.gov